Boston Trust Walden Corp Sells 63,856 Shares of Zimmer Biomet Holdings, Inc. $ZBH

Boston Trust Walden Corp trimmed its holdings in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 10.0% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 572,928 shares of the medical equipment provider’s stock after selling 63,856 shares during the quarter. Boston Trust Walden Corp’s holdings in Zimmer Biomet were worth $51,804,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of ZBH. Main Management ETF Advisors LLC boosted its position in Zimmer Biomet by 1.0% during the 4th quarter. Main Management ETF Advisors LLC now owns 10,962 shares of the medical equipment provider’s stock valued at $986,000 after acquiring an additional 112 shares in the last quarter. Boltwood Capital Management boosted its position in Zimmer Biomet by 3.9% during the fourth quarter. Boltwood Capital Management now owns 3,866 shares of the medical equipment provider’s stock valued at $348,000 after purchasing an additional 144 shares in the last quarter. Independence Bank of Kentucky grew its stake in Zimmer Biomet by 9.7% in the fourth quarter. Independence Bank of Kentucky now owns 1,633 shares of the medical equipment provider’s stock valued at $147,000 after purchasing an additional 145 shares during the last quarter. LOM Asset Management Ltd raised its holdings in Zimmer Biomet by 21.5% in the fourth quarter. LOM Asset Management Ltd now owns 830 shares of the medical equipment provider’s stock worth $75,000 after purchasing an additional 147 shares in the last quarter. Finally, Oppenheimer & Co. Inc. lifted its position in shares of Zimmer Biomet by 0.8% during the fourth quarter. Oppenheimer & Co. Inc. now owns 20,363 shares of the medical equipment provider’s stock valued at $1,831,000 after buying an additional 152 shares during the last quarter. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Insider Transactions at Zimmer Biomet

In other Zimmer Biomet news, insider Sang Yi sold 5,000 shares of Zimmer Biomet stock in a transaction dated Friday, May 29th. The stock was sold at an average price of $82.64, for a total transaction of $413,200.00. Following the completion of the sale, the insider owned 27,251 shares of the company’s stock, valued at approximately $2,252,022.64. The trade was a 15.50% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 1.28% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on ZBH. Canaccord Genuity Group set a $83.00 price target on shares of Zimmer Biomet in a report on Wednesday, April 29th. Wells Fargo & Company decreased their target price on shares of Zimmer Biomet from $98.00 to $90.00 and set an “equal weight” rating for the company in a research report on Wednesday, April 29th. Citigroup lowered their target price on shares of Zimmer Biomet from $95.00 to $93.00 and set a “neutral” rating for the company in a research note on Thursday, May 28th. Barclays cut their price target on shares of Zimmer Biomet from $100.00 to $94.00 and set an “underweight” rating on the stock in a report on Wednesday, April 29th. Finally, Truist Financial reiterated a “hold” rating and set a $92.00 price objective (down from $98.00) on shares of Zimmer Biomet in a report on Wednesday, April 29th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, twelve have assigned a Hold rating and three have issued a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $102.70.

Zimmer Biomet Stock Up 4.0%

ZBH stock opened at $87.50 on Friday. The stock has a market capitalization of $16.93 billion, a PE ratio of 22.73, a price-to-earnings-growth ratio of 2.48 and a beta of 0.46. Zimmer Biomet Holdings, Inc. has a 52 week low of $79.12 and a 52 week high of $108.29. The company has a quick ratio of 0.95, a current ratio of 1.73 and a debt-to-equity ratio of 0.50. The firm has a 50 day moving average of $86.20 and a 200 day moving average of $89.83.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings results on Tuesday, April 28th. The medical equipment provider reported $2.09 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.86 by $0.23. Zimmer Biomet had a net margin of 9.05% and a return on equity of 13.24%. The business had revenue of $2.09 billion for the quarter, compared to analyst estimates of $2.07 billion. During the same quarter in the prior year, the business posted $1.81 EPS. Zimmer Biomet’s revenue for the quarter was up 9.3% compared to the same quarter last year. Zimmer Biomet has set its FY 2026 guidance at 8.400-8.550 EPS. Sell-side analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.48 earnings per share for the current year.

Zimmer Biomet Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Thursday, June 25th will be paid a $0.24 dividend. The ex-dividend date is Thursday, June 25th. This represents a $0.96 dividend on an annualized basis and a yield of 1.1%. Zimmer Biomet’s dividend payout ratio (DPR) is 24.94%.

Zimmer Biomet Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.